Results 221 to 230 of about 2,555,654 (307)

Patient‐specific genomic measurable residual disease markers for monitoring acute myeloid leukaemia and myeloid malignancy

open access: yesBritish Journal of Haematology, EarlyView.
Standardised DNA based measurable residual disease (MRD) monitoring is possible for acute myeloid leukaemia (AML) and myeloid malignancy patients. Targeted next‐generation sequencing (NGS) and RNA‐seq permit marker development for clinically identified lesions and whole genome sequencing (WGS) permits MRD marker development in patients without ...
Libby Huang   +45 more
wiley   +1 more source

Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukemia in chronic phase”.

open access: yes, 1993
as active member of the Italian Cooperative Study Group on Chronic Myeloid Leukemia   +1 more
core   +1 more source

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia. [PDF]

open access: yesJ Cutan Pathol
Christie-Nguyen B   +5 more
europepmc   +1 more source

Algorithms in Allergy: Diagnosis of Hypereosinophilic Syndromes, 2026 Update

open access: yes
Allergy, EarlyView.
Guillaume Lefèvre   +5 more
wiley   +1 more source

Prospective phase I study of nivolumab to promote graft‐versus‐tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation

open access: yesBritish Journal of Haematology, EarlyView.
Baseline immunophenotype and gene expression predict suitability for salvage nivolumab in patients with relapsed/refractory haematological malignancy. Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune ...
Trung Q. Ngo   +7 more
wiley   +1 more source

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia. [PDF]

open access: yesHemasphere
Pagani IS   +25 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy